Margaret A. Tempero, MD

Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF

Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program; Professor of Medicine, Division of Hematology and Oncology, UCSF

Cancer Center Program Membership

Molecular Oncology

Research Summary

I am Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program. My research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. I was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. My group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials, and currently is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. I directed the first GI SPORE devoted to pancreatic cancer when I was on the faculty of the University of Nebraska and subsequently led the NCI-funded U54 Molecular Target Assessment Team at UCSF. I also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. I have served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. I also serve as co-chair on the Pancreas Task Force Tissue Acquisition Working Group for the NCI intergroup and co-organized the State of the Science meeting on pancreatic cancer at the NCI.

I have extensive experience in scientific review and administration, training and oversight. I co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for three years and spent nine years of service teaching this course and similar courses in Europe and Australia. I was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (two-year term) of the NCI Board of Scientific Counselors Subcommittee A. I am on the External Advisory Boards of the Pancreas SPORE at the University of Alabama in Birmingham/University of Minnesota and the Mayo Clinic.

I am, or have been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. I have held many appointments at AACR and ASCO and served as a member of the ASCO Board of Directors and as ASCO President in 2004. I served as a member of the Oncology Drug Advisory Committee for the FDA from 2007-2011. I served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, and Chief of the Division of Medical Oncology at UCSF (2000-2007) and Deputy Director and Director of Research Programs at the HDFCCC from 2000 to 2012.

Research Funding

  • September 15, 2014 - August 31, 2016 - Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R21CA184429
  • August 5, 1999 - September 29, 2012 - Cancer Center Support Grant, Co-Investigator. Sponsor: NIH/NCI, Sponsor Award ID: P30CA082103
  • September 26, 2001 - December 31, 2008 - Mechanism-Based Evaluations of ErbB-Targeted Agents, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: U54CA090788
  • May 15, 1998 - January 31, 2005 - SPORE IN GASTOINTESTINAL CANCER, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: P50CA072712

Education

Creighton University, Omaha, NE, B.S., 1969, Medical Technology
University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology

Honors & Awards

  • Editor-In-Chief, Journal Nat'l Comprehensive Cancer Network, 2014-Pres
  • Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF, 2012-Pres
  • Doris and Don Fisher Distinguished Professor in Clinical Research, UCSF, 2000-2012

Selected Publications

  1. Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Oncologist. 2021 Sep 10.  View on PubMed
  2. Tempero M. Something to Crow About! J Natl Compr Canc Netw. 2021 Aug 01; 19(8):881-882.  View on PubMed
  3. Tempero M. Pan-Cancer Screening: A Dream or a Nightmare. J Natl Compr Canc Netw. 2021 Jul 28; 19(7):773.  View on PubMed
  4. Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clin Cancer Res. 2021 Jul 26.  View on PubMed
  5. Tempero M. Informed Consent: Is It Really? J Natl Compr Canc Netw. 2021 Jun 30; 19(6):665.  View on PubMed
  6. Tempero M. Open Notes Are Here: Are We Ready? J Natl Compr Canc Netw. 2021 May 01; 19(5):477.  View on PubMed
  7. Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Apr 03.  View on PubMed
  8. Tempero M. Being Closer to Normal. J Natl Compr Canc Netw. 2021 Apr 01; 19(4):363.  View on PubMed
  9. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Apr 01; 19(4):439-457.  View on PubMed
  10. Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Väyrynen SA, Clancy TE, Rubinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RC, Park BS, Mori M, Nowak JA, Wolpin BM, Coussens LM. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021 Aug; 11(8):2014-2031.  View on PubMed
  11. Tempero M. It's All About Trust! J Natl Compr Canc Netw. 2021 03 02; 19(3):239.  View on PubMed
  12. Tempero M. Learning From Our Mistakes. J Natl Compr Canc Netw. 2021 02 02; 19(2):121.  View on PubMed
  13. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D, Macarulla T. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021 05; 32(5):600-608.  View on PubMed
  14. Tempero M. New Year's Resolutions - A Different Perspective. J Natl Compr Canc Netw. 2021 01 06; 19(1):1.  View on PubMed
  15. Tempero M. Lasting Effects of COVID-19: Reimbursement Reform? J Natl Compr Canc Netw. 2020 11 02; 18(11):1435.  View on PubMed
  16. Tempero M. Flirting With Disaster: COVID-19 and Cancer. J Natl Compr Canc Netw. 2020 10 01; 18(10):1291.  View on PubMed
  17. Tempero M. COVID-19 and Cancer: Unintended Consequences. J Natl Compr Canc Netw. 2020 09; 18(9):1147.  View on PubMed
  18. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020 09 01; 130(9):4704-4709.  View on PubMed
  19. Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ, HALO 109-301 Investigators . Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020 09 20; 38(27):3185-3194.  View on PubMed
  20. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Mol Ther. 2020 11 04; 28(11):2367-2378.  View on PubMed

Go to UCSF Profiles, powered by CTSI